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58 schemes that included a coverage with evidence development component, 25
that included a conditional treatment continuation component, 35 that included a
performance-linked reimbursement component, and 37 that included a patient
level financial utilization component. Each type of scheme addresses fundamental
uncertainties that exist when products enter the market. There has been a contin-
ued upward trend in terms of total schemes adopted per year and the number of
countries with performance-based schemes in place. Despite the continued enthu-
siasm, challenges persist including those related to: 1) the cost and burden of
implementation; 2) the need for consistent processes for scheme development,
data collection, reporting, and evaluation; and 3) negotiating follow-on agreements
after scheme initiation. Furthermore, the challenges faced differ by country, health
system, and product. CONCLUSIONS: There is continued enthusiasm in many
countries for using performance-based schemes for new medical products. Given
the interest to date and the potential to meet the goals of interested stakeholders,
these schemes may become a common element in health care coverage and reim-
bursement. However, significant challenges persist, and future studies are needed
regarding the attitudes and perceptions of various stakeholders as well as evalu-
ating the results and experiences with the schemes implemented thus far.
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OPINIONS ON MARKET ACCESS NEEDS DIFFER BETWEEN CULTURES AND
STAKEHOLDER SECTORS – RESULTS OF A SURVEY OF ISPOR DELEGATES
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OBJECTIVES: To determine whether stakeholders’ opinions on market access is-
sues, in particular the need for QALYs, and risk-sharing, differ by sector and geo-
graphical location.METHODS: A self-completion questionnaire was presented to a
cross section of delegates at the 13th European ISPOR Conference 2010. The ques-
tionnaire comprised 7 items, with both ordinal-polytomous Likert scales and open
ended responses. Analyses were performed to discriminate between the stake-
holder groups including Pearson Chi-squared test of independence, cross-tabula-
tions, and other descriptive statistics for nominal categorical data. The level of
agreement between responder groups was obtained from Cohen’s Kappa coeffi-
cients and radar plots. RESULTS: Respondents included representatives of over 60
companies and organisations from over 30 countries. Highly significantly different
responses were observed between members from European and non-European
countries, with the greatest overall level of agreement being between the industry
and academic sectors (87.5%, K0.75). Fewer respondents from European countries
favoured the use of the QALY than those from non-European countries (31.8% vs.
69.2%), whilst significantly more academics favoured the QALY than either indus-
try or agency respondents (62.1% vs 36.6% vs. 21.4% respectively). More academics
felt that manufacturers should offer patient access schemes (PAS) routinely (41.4%
vs. 19.4% vs. 14.3%). Of non-European respondents, 50.0% felt risk sharing should
form part of all health technology assessments compared with only 25% of respon-
dents from European countries. The majority of non-European respondents (53.8%)
expressed the need for manufacturers to provide PAS routinely; only 16.3% of Eu-
ropean respondents agreed. Only 13.3% of respondents from European countries
thought indirect comparisons are a substitute for head-to-head trials, compared
with 38.5% of respondents from non-European countries. No other significant dif-
ferences in opinions on the need for cost-utility analysis or cost-per-QALY thresh-
olds were found. CONCLUSIONS: Opinions on market access related issues differ
significantly between European and non-European ISPOR members, and between
stakeholder groups.
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OBJECTIVES: With payors increasingly looking at ways of cutting pharmaceutical
reimbursement costs, pharmaceutical companies need to consider creative solu-
tions to market access for new compounds. The objective of this research was to
examine the most recent global trends for 2010 and 2011 in pharmaceutical risk-
sharing agreements, which are now a critical part of market access strategies in
many countries. METHODS: Secondary research was conducted examining reim-
bursement decisions around the world, with a special focus on Australia, Belgium,
Canada, China, France, Germany, Hungary, Italy, The Netherlands, New Zealand,
Poland, Spain, UK and United States. This was supplemented by primary research
with payors, government agencies and HTA organisations through interviews in
native languages to understand the role which risk-sharing agreements have – or
have not – played in their respective markets. RESULTS: Forty-five new risk-shar-
ing agreements were found under the period of review (January 2010-May 2011),
nearly double the total for 2009. Of the new agreements, the majority were finance-
based agreements, though there were six new examples of performance-based
agreements. 40% of the new agreements were concluded with the UK’s NICE, whilst
Australia and Italy remain other important markets in this area. However, a signif-
icant number of newer countries are beginning to see these agreements, including
Belgium, Hungary, Poland and New Zealand, and interest is widening in emerging
markets. Around half of the agreements were in the oncology area, but there are
signs that risk-sharing is becoming increasingly prominent in other therapeutic
areas, including blood disease, mental health, pain treatment, immunology, oph-
thalmology and cardiovascular care. CONCLUSIONS: Risk-sharing agreements are
a reality for pharmaceutical companies in many key markets, and need at least to
be considered as an alternative market access strategy in certain therapeutic areas.
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OBJECTIVES: In Korea, although drug price has continuously decreased due to
many price reduction mechanisms, the volume has been increasing. Because this
risen volume is considered a main contributor of increasing pharmaceutical ex-
penditure, the government adopted price-volume negotiation in 2006. This study
attempted to analyze the status of price-volume (PV) negotiation and identify prob-
lems and the solutions to improve the price-volume negotiation. METHODS: The
comprehensive questionnaire was designed based on Korea price negotiation
guideline and validated by three pilot interviewers. It consisted of the status,
awareness, satisfaction, problems/solutions. Pharmaceutical company’s people
involved in market access were interviewed face-to-face. The response rate was
80% (n34). Multinational and local company accounted for 59% and 41%,
respectively. RESULTS: Most important factors for PV negotiation were budget
impact and price from the Korean PV formula. 69% of 16 PV cases were derived from
the price calculated by PV formula and only 42% reached the consensus on budget
impact because of different data sources. Most respondents agreed with the objec-
tive of the risk-sharing system but the overall satisfaction was significantly low, 1.9
out of 5-point scale. Main reasons are unpredictability of selecting PV product,
discreditable NHIC data and non-transparency of the negotiation process. Also,
76.5% of respondents was against PV negotiation because of the government’s
unnecessary intervention and concerns on weakening the pharmaceutical indus-
try. Especially, respondents worried about profit deterioration due to duplicated
price reduction. In response, they suggested the advanced PV model with a more
specific PV inclusion criteria and the choice between price reduction and pay-back.
Additionally, generic promotion and pay-back system activation to contain the
drug expenditure are preferred over price-volume negotiation. CONCLUSIONS:
The price-volume negotiation in Korea must be improved to motivate the pharma-
ceutical industry through adopting their opinions on advanced PV model which
includes pay-back.
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OBJECTIVES: Pharmaceutical pricing decisions are adopted in a context of uncer-
tainty with regard to the efficacy and safety of the drug as well as to their budgetary
implications. Traditionally, pharmaceutical firms have received a fixed price per
unit sold regardless of health outcomes and sales volume. This pricing policy tends
to increase health budgets and may restrict the access to pharmaceutical innova-
tions for patients. Recently, health authorities have begun to use risk-sharing con-
tracts based on health outcomes to cope with the aforementioned problem. In this
paper, we carry out a theoretical modelling of the risk-sharing contracts, empha-
sizing the variables and parameters that are relevant in the relationship between
health authorities and pharmaceutical firms. METHODS: We have elaborated a
theoretical model that describes the interaction between a pharmaceutical firm
and a public health authority using a two-stage game. In the first stage, the health
authority chooses the pricing policy, either paying to the firm for treated patient or
for cured patient, and in the second stage, the firm, given the pricing policy and the
prescribing behaviour of the physicians, selects the price that maximizes its ex-
pected profits. We solve the game by backward induction, using the subgame per-
fect equilibrium as the solution concept. RESULTS: Risk-sharing contracts are not
always optimal in terms of social welfare. Their optimality depends on the param-
eters of the problem, being conditioned by the prescribing behaviour of the physi-
cians, the efficacy of the drug and the monitoring costs. We characterize the para-
metric regions for which each pricing policy is socially optimal. CONCLUSIONS:
Before using risk-sharing contracts, their convenience must be addressed for each
particular case. As a necessary condition, the existence of objective quantitative
health indicators is required. Otherwise, it is difficult to implement the pricing
policy only based on cured patients.
PHP151
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MANUFACTURERS, AND HEALTH CARE WORKERS
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OBJECTIVES: Managed entries (MEs) are innovative pricing and reimbursement
agreements aiming to share the risk related to the introduction of new, high-cost
drugs between the payer and the manufacturer. This study aims to review evidence
on the impact of MEs on payer, patients, manufacturer, and health care workers
and to analyse emerging trends in managed entries at international level.
METHODS:A systematic literature review (grey and peer-reviewed) was performed
complemented by search of health technology assessment agency’s websites and
selective interviews with decision makers in key European countries. RESULTS:
Evidence exists of improved cost-effectiveness and lower drug price following the
implementation of coverage with evidence development in Sweden. Data from
France shows that price-volume agreements led to rebates totalling around 3% of
the total drugs bill. Evidence from Italy shows that authorization with a risk-shar-
ing agreement was associated with more rapid patient access in comparison to
authorization without such an agreement. It is unclear whether managed entries
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constitute a reward for manufacturers, however, various benefits have been re-
ported such as reimbursement for drugs which received an initial negative recom-
mendation (e.g. bortezomib and trabectedin, UK) and competitive advantage in the
form of better formulary position (sitagliptin & sitagliptin  metformin, USA); not
to mention the possibility of granting discounts while leaving list prices un-
touched. Considerable administrative burden is placed on health care staff due to
the diversity of existing schemes, the complexities linked with retrospective reim-
bursement, and lack of management capacity at current staffing levels.
CONCLUSIONS: Although evidence on the impact of MEs is patchy, the systematic
literature review showed that there are already lessons to be learnt. Preliminary
findings seem to suggest that MEs have indeed the potential of meeting payer,
patient, and manufacturer expectations, yet important threats such as implemen-
tation difficulties, administrative burden and lack of management capacity need to
be addressed.
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OBJECTIVES: In the UK, Patient Access Schemes (PAS) have become common in
health technology submissions, and have been instrumental in enhancing the
availability of otherwise non cost-effective treatments. Despite notable efforts to-
wards recognising and reducing the administrative impact of PAS on frontline
staff, evidence suggests that they still result in a significant burden. The study
presented here attempted to assess the burden of PAS administration, and how
this could change if and when the planned changes to the UK healthcare system
are enacted. METHODS: A literature search was conducted and freedom-of-infor-
mation requests were sent to the Patient Access Scheme Liaison Unit (PASLU) for
data on PAS administration. A questionnaire developed from our previous pilot
study on the administrative burden of PAS was distributed to hospital pharmacists
across the UK, and a call for participants was hosted on the Royal Pharmaceutical
Society website.RESULTS:Value Based Pricing (VBP) is expected to be introduced in
the UK once the current Pharmaceutical Price Regulation Scheme comes to an end.
PAS approved before this point will continue to be used, although additional PAS
may not be introduced under VBP. It is unclear from the available literature how
this will affect the role of PASLU and the administration of the remaining PAS. The
return-rate for our questionnaire was low; however, responders voiced similar
concerns to those recorded in our pilot study, namely the poor recognition of the
burden of PAS and the resources required to manage them. Responders were also
unclear about how administration of PAS would change with the move to VBP.
CONCLUSIONS:The role of PAS in the changing NHS, and the burden such schemes
could entail, is uncertain. Clear guidelines on the impact of healthcare reform are
necessary, alongside additional support to facilitate effective PAS implementation
even after VBP is introduced.
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OBJECTIVES: Pharmaceutical patents have been a useful instrument to promote
innovations in some fields. The signature of the TRIP agreement by the World
Trade Organization (WTO) in 1994 has implied the generalization of a strong patent
system. The objectives of this study is to review some existing alternatives to
patents that may both reduce their negative impact in the accessibility to new
drugs of patients from less developed countries and promote research in neglected
diseases. METHODS: We have reviewed the literature on this field and identified
different alternatives proposed by international institutions as well as by non gov-
ernmental organisations. We describe the options and assess their potential im-
pact on public health. RESULTS: There are several proposals: i) the intensive use of
exceptions and flexibility conditions of Doha=s Declaration, especially, compulsory
licensing, ii) the volunteer licensing through the “patent pool”, iii) GSPOA initiative
that targets the identification and assessment of priorities dealing with R&D re-
ferred to diseases prevalent among the developing countries, iv) the approach
based on prizes, aiming to incentive innovation through competition by separating
the cost of R&D and the price of the drug; v) the Advance Market Commitments to
ex-ante obtain the commitment to fund through donations the new agent once it
has been developed, and vi) the Priority Review Vouchers that provides incentives
to invest in drugs for neglected tropical diseases by offering a transferable voucher
to the pharmaceutical firm that allows a priority review process for the authorisa-
tion of another agent. CONCLUSIONS: Most of the solutions are partial and do not
pursue a radical change in the current patent system. In spite of these proposals,
there are still many diseases with no treatment as the market does not guarantee
a return.
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OBJECTIVES:We aimed to explore the key organizational elements and the degrees
of autonomy that is granted to Iranian corportized hospital (trustees hospitals)
affiliated to Iranian ministry of health after the Iranian health system decentral-
ization reform. METHODS: : All 18 Iranian corportized hospitals (that meet our
criteria) involved to the study. In all, 27 Hospital Top Managers were interviewed
(82% response rate). The semi-structured interview questions were developed us-
ing the Preker and Harding organizational reform Model and in-depth interviews.
The “framework” method was used for the analysis. RESULTS: Nine themes ex-
plain the key organizational elements include: decision right in “strategic”, “hu-
man resources”, “financial” and “physical resources” management, “product” and
“procurement” market exposure, “residual claimant” and “social functions”. Deci-
sion right in “strategic”, “human resources” and “physical resources” management
was very limited. The hospitals were permitted to generate revenue (fee-for- ser-
vices) but weren’t the residual claimant, completely. The hospital was exposed to
product market but limited in procurement market (ceiling payment). Hierarchical
and financial accountability were the main accountability mechanism. Several
insurance programs and governmental budget were used to protect poor people.
CONCLUSIONS:We can see a kind of unbalanced and inconsistent autonomy. More
decision right in “strategic” and “human resources” management, and procure-
ment market should be granted; and also the hospital needs to be the residual
claimant. Government needs a regulatory and accountability mechanism to guar-
antee hospitals performance and balance the revenue generating and social values
objectives.
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REVIEW OF COST EFFECTIVENESS MODELS OF HIGH BUDGET IMPACT DRUGS
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OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC
and the allocation of $1.1 billion for comparative effectiveness research by the
United States, are strong indicators of trends in pricing and reimbursement that
are likely to be observed in the future. To gain an additional insight into these
trends, we analyzed the cost effectiveness studies for the top twenty highest selling
drugs ($90-100B worldwide sales). METHODS: The Top 20 drugs were selected
based on their worldwide sales. For this analysis, we segmented these drugs into
categories as primary care, specialty, small molecules, biologics, therapy areas and
availability of generic alternatives. We analyzed the cost effectiveness studies that
were published in peer-reviewed journals. Search was conducted using generic
names of the drugs and the phrase cost effectiveness in abstract of the published
study. RESULTS:During 2005-2010, the number of published studies on cost effec-
tiveness have increased by more than 30%. There is a large variability in CERs for
same drugs for different indications, in some cases also varying by biomarkers.
Primary care drugs had lower and less variable CERs than specialty drugs. Varia-
tions also exist in methodology used by different groups in modeling cost effec-
tiveness, especially for time horizon and comparator. Majority of primary care
drugs were modeled for a time horizon of 35-40 years or lifetime to demonstrate
cost effectiveness. CONCLUSIONS: This analysis shows the range, variability and
methods used for calculation of ICER values for these high budget impact drugs and
provides lessons for executives and policy makers.
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OBJECTIVES: Cancer drugs are the world’s highest selling category of therapeutic
products. Due to their premium price and budget impact, several new drug reim-
bursement models have been implemented worldwide by public and private pay-
ers. These models have potential implications for coverage and reimbursement of
all branded products. This study reviewed recent cancer drug reimbursement mod-
els and developed lessons and implications for future products. METHODS: Re-
viewed cancer drug reimbursement schemes in developed and emerging markets.
Interviewed payers and KOLs to develop lessons and implications for future
products. RESULTS: Public and private payers worldwide have implemented sev-
eral new models for cancer drug reimbursement to manage budgets and control
costs. In the US, private payers are piloting single source compendia and third party
protocols (eg. P4 Oncology) to limit off-label use of cancer drugs. In the UK, NICE has
successfully negotiated lower price and discounts for first few cycles of therapy. In
Italy, AIFA has implemented registry based patient access for cancer drugs. In
India, several manufacturers have implemented novel pricing strategy for first few
cycles of therapy. In Germany, IQWIG has proposed to use correlations between
surrogate endpoints and patient relevant outcomes to determine value of cancer
drugs. Due to increased cost pressure on payers, such models are likely to inspire
novel reimbursement schemes for other branded products.CONCLUSIONS:Cancer
drug reimbursement models are setting new benchmark for payers to manage
access and control costs. These models have significant implications for other
expensive branded products.
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USING THE CEAC FOR VALUE BASED PRICING: DON’T CHANGE THE GOALPOSTS
Roberts G
Double Helix Consulting, London, UK
ISSUE One approach under consideration for the proposed value based pricing of
pharmaceutical is the UK is to have different willingness to pay thresholds. How-
ever these are problematic to define, lack transparency and not readily understood
by the wider public. OVERVIEW Different willingness to pay thresholds have been
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